Pulmonary fibrosis: from pathogenesis to clinical decision-making
- PMID: 37716906
- DOI: 10.1016/j.molmed.2023.08.010
Pulmonary fibrosis: from pathogenesis to clinical decision-making
Abstract
Pulmonary fibrosis (PF) encompasses a spectrum of chronic lung diseases that progressively impact the interstitium, resulting in compromised gas exchange, breathlessness, diminished quality of life (QoL), and ultimately respiratory failure and mortality. Various diseases can cause PF, with their underlying causes primarily affecting the lung interstitium, leading to their referral as interstitial lung diseases (ILDs). The current understanding is that PF arises from abnormal wound healing processes triggered by various factors specific to each disease, leading to excessive inflammation and fibrosis. While significant progress has been made in understanding the molecular mechanisms of PF, its pathogenesis remains elusive. This review provides an in-depth exploration of the latest insights into PF pathophysiology, diagnosis, treatment, and future perspectives.
Keywords: diagnostic and therapeutic management; interstitial lung diseases; pulmonary fibrosis.
Copyright © 2023 Elsevier Ltd. All rights reserved.
Similar articles
-
Interstitial lung diseases.Lancet. 2022 Sep 3;400(10354):769-786. doi: 10.1016/S0140-6736(22)01052-2. Epub 2022 Aug 11. Lancet. 2022. PMID: 35964592 Review.
-
Diagnosis and Management of Fibrotic Interstitial Lung Diseases.Clin Chest Med. 2021 Jun;42(2):321-335. doi: 10.1016/j.ccm.2021.03.008. Clin Chest Med. 2021. PMID: 34024407 Review.
-
Recent advances in the pathogenesis and clinical evaluation of pulmonary fibrosis.Eur Respir Rev. 2012 Mar 1;21(123):48-56. doi: 10.1183/09059180.00007611. Eur Respir Rev. 2012. PMID: 22379174 Free PMC article. Review.
-
Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases.Eur Respir Rev. 2018 Dec 21;27(150):180078. doi: 10.1183/16000617.0078-2018. Print 2018 Dec 31. Eur Respir Rev. 2018. PMID: 30578337 Free PMC article. Review.
-
Estimates of epidemiology, mortality and disease burden associated with progressive fibrosing interstitial lung disease in France (the PROGRESS study).Respir Res. 2021 May 24;22(1):162. doi: 10.1186/s12931-021-01749-1. Respir Res. 2021. PMID: 34030695 Free PMC article.
Cited by
-
GLP-1R activation attenuates the progression of pulmonary fibrosis via disrupting NLRP3 inflammasome/PFKFB3-driven glycolysis interaction and histone lactylation.J Transl Med. 2024 Oct 21;22(1):954. doi: 10.1186/s12967-024-05753-z. J Transl Med. 2024. PMID: 39434134 Free PMC article.
-
The role of the cGAS-STING pathway in chronic pulmonary inflammatory diseases.Front Med (Lausanne). 2024 Oct 30;11:1436091. doi: 10.3389/fmed.2024.1436091. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39540037 Free PMC article. Review.
-
Use quercetin for pulmonary fibrosis: a preclinical systematic review and meta-analysis.Inflammopharmacology. 2025 Apr;33(4):1879-1897. doi: 10.1007/s10787-025-01678-1. Epub 2025 Mar 4. Inflammopharmacology. 2025. PMID: 40038212
-
Extracellular Vesicles in Idiopathic Pulmonary Fibrosis: Pathogenesis, Biomarkers and Innovative Therapeutic Strategies.Int J Nanomedicine. 2024 Nov 25;19:12593-12614. doi: 10.2147/IJN.S491335. eCollection 2024. Int J Nanomedicine. 2024. PMID: 39619058 Free PMC article. Review.
-
Roles of gut microbiome-associated metabolites in pulmonary fibrosis by integrated analysis.NPJ Biofilms Microbiomes. 2024 Dec 19;10(1):154. doi: 10.1038/s41522-024-00631-4. NPJ Biofilms Microbiomes. 2024. PMID: 39702426 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical